Supriya Lifescience credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22Mar 2022
0.00.00.016.621.3
−79.2−79.2−75.0−141−207
0.00×0.00×0.00×0.02×0.03×
−0.08×−0.08×−0.09×−0.20×−0.34×
−0.27×————
0.0%0.0%0.0%2.3%3.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health
₹ CrorePeersSTARSPARCTHYROCARESHILPAMEDVIYASHRUBICONYATHARTHPARKHOSPS
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2026
Total Debt21.316.60.00.00.0
Net Debt-206.6-141.0-75.0-79.2-79.2
Total Debt/Equity0.030.020.000.000.00
Net Debt/Equity-0.34-0.20-0.09-0.08-0.08
Net Debt/EBITDA————-0.27
Total Debt/Total Capital %3.342.320.000.000.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.